Danicamtiv
As of the edition of 20 October 2026, Danicamtiv is a small molecule: in active development; acts on MYH6, MYH7 and MYH7B and 4 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 9, 1 stopped early
- Disease areas
- Heart and blood vessels; Inherited and neonatal; Bones, joints and muscles; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 2 | 1 | 0 | 1 |
| Phase 3 | 2 | 0 | 2 | 0 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Lead sponsor of trials | 2017 to now |
| Kardigan | Lead sponsor of trials | 2026 to now |